Mysimba - direct healthcare professional communication (DHPC)

bupropion hydrochloride / naltrexone hydrochloride

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC) : Mysimba (naltrexone/bupropion): long-term cardiovascular risk and new recommendations on annual assessment

Dissemination date: 29/05/2025

Key facts

• Medicine name:
  Mysimba
• Active substance:
  • bupropion hydrochloride
  • naltrexone hydrochloride
• Procedure number:
  EMEA-H-A-20-1530
• Regulatory outcome:
  Variation
• DHPC type:
  Adverse event
• Human ATC codes:
  A08AA
• Dissemination date:
  29/05/2025